ID   MGH125
AC   CVCL_DH50
DR   cancercelllines; CVCL_DH50
DR   GEO; GSM1568548
DR   GEO; GSM1579487
DR   Wikidata; Q54905474
RX   PubMed=25758528;
RX   PubMed=26828195;
CC   Characteristics: Erlotinib resistant (PubMed=25758528).
CC   Sequence variation: Gene deletion; HGNC; HGNC:9884; RB1; Zygosity=Heterozygous (PubMed=25758528).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Unspecified (PubMed=25758528).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (PubMed=25758528).
CC   Sequence variation: Mutation; HGNC; HGNC:9884; RB1; Simple; p.Arg445Ter (c.1333C>T); ClinVar=VCV000013071; Zygosity=Heterozygous (PubMed=25758528).
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 10-04-25; Version: 11
//
RX   PubMed=25758528; DOI=10.1038/ncomms7377; PMCID=PMC4357281;
RA   Niederst M.J., Sequist L.V., Poirier J.T., Mermel C.H.,
RA   Lockerman E.L., Garcia A.R., Katayama R., Costa C., Ross K.N.,
RA   Moran T., Howe E., Fulton L.E., Mulvey H.E., Bernardo L.A.,
RA   Mohamoud F., Miyoshi N., VanderLaan P.A., Costa D.B., Janne P.A.,
RA   Borger D.R., Ramaswamy S., Shioda T., Iafrate A.J., Getz G.,
RA   Rudin C.M., Mino-Kenudson M., Engelman J.A.;
RT   "RB loss in resistant EGFR mutant lung adenocarcinomas that transform
RT   to small-cell lung cancer.";
RL   Nat. Commun. 6:6377.1-6377.10(2015).
//
RX   PubMed=26828195; DOI=10.1038/nm.4040; PMCID=PMC4900892;
RA   Hata A.N., Niederst M.J., Archibald H.L., Gomez-Caraballo M.,
RA   Siddiqui F.M., Mulvey H.E., Maruvka Y.E., Ji F., Bhang H.-e.C.,
RA   Krishnamurthy Radhakrishna V., Siravegna G., Hu H.-C., Raoof S.,
RA   Lockerman E.L., Kalsy A., Lee D., Keating C.L., Ruddy D.A., Damon L.J.,
RA   Crystal A.S., Costa C., Piotrowska Z., Bardelli A., Iafrate A.J.,
RA   Sadreyev R.I., Stegmeier F., Getz G., Sequist L.V., Faber A.C.,
RA   Engelman J.A.;
RT   "Tumor cells can follow distinct evolutionary paths to become
RT   resistant to epidermal growth factor receptor inhibition.";
RL   Nat. Med. 22:262-269(2016).
//